Madrid - PharmaMar (MSE: PHM), along with Jazz Pharmaceuticals plc (Nasdaq: JAZZ), has announced today that the International Association for the Study of Lung Cancer (IASLC) has released the abstracts to be presented during the IASLC 2020 World Conference on Lung Cancer, which will be held virtually from January 28th to 31st .

One oral presentation and three posters will be presented on ZepzelcaTM (lurbinectedin) during the congress.

In the oral presentation, new data on the lurbinectedin combination with irinotecan in relapsed Small Cell Lung Cancer (SCLC) will be presented, under the abstract 'Lurbinectedin with irinotecan in relapsed small cell lung cancer. Results from the expansion stage of a phase I-II trial'.

This combination of lurbinectedin and irinotecan demonstrated efficacy in SCLC after failure of first-line therapy, including 'remarkable activity in patients with resistant disease (CTFI

(C) 2021 Electronic News Publishing, source ENP Newswire